Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.85    0.05 (2.78%)
Bid:
1.70
Ask:
2.00
Spread: 0.30 (17.647%)
Market Cap: £8.08m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Rule 2.9 Announcement

16 Apr 2024 13:08

RNS Number : 8404K
Renalytix PLC
16 April 2024
 

 

 

Renalytix plc

("Renalytix" or the "Company")

 

Rule 2.9 Announcement

 

LONDON and SALT LAKE CITY, 16 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), in accordance with Rule 2.9 of the City Code on Takeovers and Mergers ("Takeover Code") and further to the announcement on 15 April 2024, confirms that its issued share capital consists of 126,219,016 ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") following the issuance of the Initial Tranche Shares of 2,666,667 Ordinary Shares this morning.

 

The Company also has a sponsored Level III ADR programme. The ADSs are traded on the Nasdaq Global Market and Citibank N.A. acts as the depositary for the programme. Each ADS represents two Ordinary Shares.  No shares are held in treasury. The total number of voting rights in the Company is therefore 126,219,016.

 

The International Securities Identification Number for the Ordinary Shares is GB00BYWL4Y04.

 

The International Securities Identification Number for the ADSs is US75973T1016.

 

Capitalised terms used but not defined in this announcement have the meanings given to them in the announcement dated 15 April 2024, unless the context provides otherwise.

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

 

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 

Walbrook PR Limited

Paul McManus / Alice Woodings /

Charlotte Edgar

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654 /

07884 664 686

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

Disclosure requirements of the Takeover Code

Under Rule 8.3(a) of the Takeover Code, any person who is interested in one per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

 

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in one per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTFLFIFSDIRLIS
Date   Source Headline
29th May 20264:24 pmRNSHolding(s) in Company
27th May 202611:20 amRNSHolding(s) in Company
18th May 20263:52 pmRNSHolding(s) in Company
5th May 20263:26 pmRNSHolding(s) in Company
5th May 20269:39 amRNSHolding(s) in Company
1st May 20269:23 amRNSHolding(s) in Company
29th Apr 20264:17 pmRNSHolding(s) in Company
23rd Apr 202611:46 amRNSHolding(s) in Company
23rd Apr 202611:42 amRNSHolding(s) in Company
22nd Apr 20267:00 amRNSKey milestones achieved for kidneyintelX.dkd
16th Apr 20266:04 pmRNSHolding(s) in Company
16th Apr 20269:16 amRNSHolding(s) in Company
9th Apr 20264:29 pmRNSHolding(s) in Company
7th Apr 20265:25 pmRNSHolding(s) in Company
7th Apr 20265:24 pmRNSHolding(s) in Company
30th Mar 20263:41 pmRNSHolding(s) in Company
26th Mar 20267:00 amRNSHalf-year Report
18th Mar 20261:55 pmRNSHolding(s) in Company
17th Mar 202611:22 amRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
27th Feb 20267:00 amRNSHolding(s) in Company
13th Feb 20262:30 pmRNSFurther CEO Share Purchase
13th Feb 20267:00 amRNSDirector/PDMR Shareholding
12th Feb 20267:01 amRNSDirector/PDMR Share Purchase
12th Feb 20267:00 amRNSCEO Share Purchase
11th Feb 20267:00 amRNSH1 Trading update
21st Jan 20263:20 pmRNSHolding(s) in Company
15th Jan 20264:51 pmRNSHolding(s) in Company
12th Jan 20267:00 amRNSThree kidneyintelX.dkd Clinical Integrations
9th Jan 20262:43 pmRNSHolding(s) in Company
6th Jan 20264:28 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
17th Dec 20251:42 pmRNSHolding(s) in Company
16th Dec 20251:51 pmRNSHolding(s) in Company
9th Dec 202510:57 amRNSResult of AGM
9th Dec 20257:00 amRNSAGM Statement
27th Nov 20252:39 pmRNSHolding(s) in Company
25th Nov 20253:44 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSPlan to Implement ADS Ratio Change
12th Nov 20257:00 amRNSPivotal kidneyintelX.dkd data published
5th Nov 20254:02 pmRNSHolding(s) in Company
4th Nov 20256:05 pmRNSPublication of Annual Report & Notice of AGM
3rd Nov 202512:05 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSAudited Full Year Fiscal 2025 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.